Serotiny Appoints Chad May, Ph.D., as Chief Scientific Officer

Chad May, Ph.D., has been named Chief Scientific Officer of Serotiny. Dr. May will oversee the research and development of Serotiny’s novel therapeutics programs in her new role. He brings to Serotiny extensive knowledge and proficiency gained from leading oncology research and development programs across a wide range of tumor types and therapeutic modalities for more than 20 years. He most recently served as senior vice president of Research and Development at Maverick Therapeutics (acquired by Takeda in April 2021).

Serotiny is a therapeutic discovery company that designs new genes for next-generation cell & gene therapies.

Serotiny has 3 investors including 8VC And NanoDimension and has raised $3.1M to date.